Skip to main content
Fig. 1 | Health and Quality of Life Outcomes

Fig. 1

From: Patient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes: analysis of a randomized clinical trial

Fig. 1

Visual Analog Scale - Injection Site Pain evaluation from baseline to endpoint. Abbreviations: BID = twice daily; SD = standard deviation; TID = thrice daily; VAS = visual analog scale. *Actual mean values of patients on U100 insulins ± SD are from corrected CRF data. **p-values are <0.05 for visit 12 and visit 16 when least square mean change from baseline are calculated (−7.36 TID, -5.85 BID visit 12 and -5.60 TID, -6.47 BID visit 16)

Back to article page

Health and Quality of Life Outcomes

ISSN: 1477-7525

Contact us